id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-4198-0013,FDA,FDA-2016-N-4198,Testimony from Nicholas Mendola,Other,Testimony,2017-06-02T04:00:00Z,2017,6,2017-06-02T04:00:00Z,,2017-06-02T20:26:21Z,,0,0,0900006482680cbd
FDA-2016-N-4198-0012,FDA,FDA-2016-N-4198,Testimony from Adriane Fugh-Berman,Other,Testimony,2017-06-02T04:00:00Z,2017,6,2017-06-02T04:00:00Z,,2017-06-02T20:20:49Z,,0,0,0900006482680c8f
FDA-2016-N-4198-0002,FDA,FDA-2016-N-4198,"Public Meeting on Patient-Focused Drug Development for Sarcopenia;
Request for Comments; Correction",Notice,Correction,2017-03-16T04:00:00Z,2017,3,2017-03-16T04:00:00Z,,2017-03-16T14:20:08Z,2017-05247,0,0,090000648250c552
FDA-2016-N-4198-0001,FDA,FDA-2016-N-4198,"Public Meeting on Patient-Focused Drug Development for Sarcopenia;
Request for Comments",Notice,Request for Comments,2016-12-14T05:00:00Z,2016,12,2016-12-14T05:00:00Z,2017-06-07T03:59:59Z,2017-06-07T01:02:42Z,2016-29998,0,0,0900006482407424